Drug interactions
Glimepiride-pioglitazone + Tecovirimat
Severity: Moderate
Glimepiride-pioglitazone and Tecovirimat: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tecovirimat weakly inhibits CYP2C8 and CYP2C19, and may modestly raise pioglitazone exposure (CYP2C8 substrate). Glimepiride, a CYP2C9 substrate, is less affected. Increased glucose lowering is possible.
What this interaction means in plain words
Glimepiride-pioglitazone and Tecovirimat can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Glimepiride-pioglitazone belongs to Endocrine; Tecovirimat belongs to Miscellaneous.
Why it happens
Weak inhibition of CYP2C8 by tecovirimat reduces pioglitazone metabolism.
What to do
Monitor blood glucose and signs of hypoglycemia or fluid retention during the short tecovirimat course. Adjust antidiabetic doses if needed.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Glimepiride-pioglitazone and Tecovirimat, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Glimepiride-pioglitazone
Other interactions of Tecovirimat
- Bosentan + Tecovirimat Moderate
- Cyclosporin + Tecovirimat Moderate
- Darunavir + Tecovirimat Moderate
- Ethinyl estradiol-drospirenone + Tecovirimat Moderate
- Ethinyl estradiol-levonorgestrel + Tecovirimat Moderate
- Maraviroc + Tecovirimat Moderate
Frequently asked questions
Can I take Glimepiride-pioglitazone with Tecovirimat?
MediHelp rates the interaction as moderate. Glimepiride-pioglitazone and Tecovirimat can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tecovirimat weakly inhibits CYP2C8 and CYP2C19, and may modestly raise pioglitazone exposure (CYP2C8 substrate). Glimepiride, a CYP2C9 substrate, is less affected. Increased glucose lowering is possible.
How serious is the interaction between Glimepiride-pioglitazone and Tecovirimat?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose and signs of hypoglycemia or fluid retention during the short tecovirimat course. Adjust antidiabetic doses if needed.
What other medicines interact with Glimepiride-pioglitazone?
MediHelp also lists interactions of Glimepiride-pioglitazone with, for example, Fluconazole, Gemfibrozil, Insulin aspart. The full list is on the Glimepiride-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
